These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

899 related items for PubMed ID: 24099873

  • 1. Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995-2011.
    Rudnick W, Liu Z, Shigayeva A, Low DE, Green K, Plevneshi A, Devlin R, Downey J, Katz K, Kitai I, Krajden S, Ostrowska K, Richardson D, Richardson S, Sarabia A, Silverman M, Simor AE, Tyrrell G, McGeer A, Toronto Invasive Bacterial Diseases Network.
    Vaccine; 2013 Dec 02; 31(49):5863-71. PubMed ID: 24099873
    [Abstract] [Full Text] [Related]

  • 2. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A, Bergsaker MA, Aaberge IS, Rønning K, Vestrheim DF.
    Vaccine; 2013 Dec 16; 31(52):6232-8. PubMed ID: 24176490
    [Abstract] [Full Text] [Related]

  • 3. The shifting epidemiology and serotype distribution of invasive pneumococcal disease in Ontario, Canada, 2007-2017.
    Wijayasri S, Hillier K, Lim GH, Harris TM, Wilson SE, Deeks SL.
    PLoS One; 2019 Dec 16; 14(12):e0226353. PubMed ID: 31834926
    [Abstract] [Full Text] [Related]

  • 4. Invasive Pneumococcal Disease Among Immunocompromised Persons: Implications for Vaccination Programs.
    Shigayeva A, Rudnick W, Green K, Chen DK, Demczuk W, Gold WL, Johnstone J, Kitai I, Krajden S, Lovinsky R, Muller M, Powis J, Rau N, Walmsley S, Tyrrell G, Bitnun A, McGeer A, Toronto Invasive Bacterial Diseases Network.
    Clin Infect Dis; 2016 Jan 15; 62(2):139-47. PubMed ID: 26354970
    [Abstract] [Full Text] [Related]

  • 5. Have changing pneumococcal vaccination programmes impacted disease in Ontario?
    Lim GH, Wormsbecker AE, McGeer A, Pillai DR, Gubbay JB, Rudnick W, Low DE, Green K, Crowcroft NS, Deeks SL.
    Vaccine; 2013 May 31; 31(24):2680-5. PubMed ID: 23597716
    [Abstract] [Full Text] [Related]

  • 6. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.
    Lacapa R, Bliss SJ, Larzelere-Hinton F, Eagle KJ, McGinty DJ, Parkinson AJ, Santosham M, Craig MJ, O'Brien KL.
    Clin Infect Dis; 2008 Aug 15; 47(4):476-84. PubMed ID: 18627249
    [Abstract] [Full Text] [Related]

  • 7. Impact of pneumococcal conjugate vaccines on burden of invasive pneumococcal disease and serotype distribution of Streptococcus pneumoniae isolates: an overview from Kuwait.
    Mokaddas E, Albert MJ.
    Vaccine; 2012 Dec 31; 30 Suppl 6():G37-40. PubMed ID: 23228356
    [Abstract] [Full Text] [Related]

  • 8. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
    Lepoutre A, Varon E, Georges S, Dorléans F, Janoir C, Gutmann L, Lévy-Bruhl D, Microbiologists of Epibac, ORP Networks.
    Vaccine; 2015 Jan 03; 33(2):359-66. PubMed ID: 25448105
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
    Klok RM, Lindkvist RM, Ekelund M, Farkouh RA, Strutton DR.
    Clin Ther; 2013 Feb 03; 35(2):119-34. PubMed ID: 23312274
    [Abstract] [Full Text] [Related]

  • 10. Four years of universal pneumococcal conjugate infant vaccination in Germany: impact on incidence of invasive pneumococcal disease and serotype distribution in children.
    van der Linden M, Weiß S, Falkenhorst G, Siedler A, Imöhl M, von Kries R.
    Vaccine; 2012 Aug 31; 30(40):5880-5. PubMed ID: 22771186
    [Abstract] [Full Text] [Related]

  • 11. Nearly complete elimination of the 7-valent pneumococcal conjugate vaccine serotypes in Tennessee.
    Halasa NB, Grijalva CG, Arbogast PG, Talbot TR, Craig AS, Griffin MR, Schaffner W.
    Pediatr Infect Dis J; 2013 Jun 31; 32(6):604-9. PubMed ID: 23348816
    [Abstract] [Full Text] [Related]

  • 12. Eradication of invasive pneumococcal disease due to the seven-valent pneumococcal conjugate vaccine serotypes in Calgary, Alberta.
    Leal J, Vanderkooi OG, Church DL, Macdonald J, Tyrrell GJ, Kellner JD.
    Pediatr Infect Dis J; 2012 Sep 31; 31(9):e169-75. PubMed ID: 22673137
    [Abstract] [Full Text] [Related]

  • 13. Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2010 Mar 12; 59(9):253-7. PubMed ID: 20224541
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23).
    American Academy of Pediatrics Committee on Infectious Diseases.
    Pediatrics; 2010 Jul 12; 126(1):186-90. PubMed ID: 20498180
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Impact of the 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in infants younger than 90 days in England and wales.
    Ladhani SN, Andrews NJ, Waight P, Borrow R, Slack MP, Miller E.
    Clin Infect Dis; 2013 Mar 12; 56(5):633-40. PubMed ID: 23175560
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.